Todd Harris - 03 Apr 2023 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: TYRA
Reported as of: 03 Apr 2023
Net transaction value: -$27,752
SEC form: 4
Accepted by SEC: 05 Apr 2023, 17:20:03 UTC
Prior SEC filing: 31 Mar 2023
Next SEC filing: 15 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Ali D. Fawaz, Attorney-in-Fact

Key filing fact

Todd Harris filed Form 4 for Tyra Biosciences, Inc. (TYRA) on 05 Apr 2023.

Key facts

This page summarizes Todd Harris's Form 4 filing for Tyra Biosciences, Inc. (TYRA).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Apr 2023, 17:20.

Change

Previous filing in this sequence was filed on 31 Mar 2023.
Current net transaction value: -$27,752.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TYRA transaction

Common Stock

Options Exercise

Transaction value: $4,500
Shares: +2,000
Change %: +0.12%
Price: $2.25^*
Shares after: 1,703,276
Date: 03 Apr 2023
Ownership: Direct

TYRA transaction

Common Stock

Sale

Transaction value: $32,252
Shares: -2,000
Change %: -0.12%
Price: $16.13
Shares after: 1,701,276
Date: 03 Apr 2023
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TYRA transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -2,000
Change %: -0.5%
Price: $0.000000
Shares after: 397,537
Date: 03 Apr 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,000
Exercise price: $2.25
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022.

Footnote F2

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 and $16.240. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

Footnote F3

1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.